In previous studies we demonstrated that ASC-EVs exerted a neuroprotective effect in an in vitro model of ALS [40] as well as in the SOD1(G93A) murine model: indeed, we showed that repeated administration of ASC-EVs improved motor performance, protected lumbar MNs, NMJs and skeletal muscles and decreased the glial cell activation in treated animals [41]. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.